Back
Speaker illustration

Doctor Ewelina Kulikowski

Calgary (Canada)

Presentations

Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial

Event: ESC Congress 2024

Topic: Fibrosis

Session: Epigenetic targets in cardiovascular disease

Access
Like
Thumbnail

Apabetalone, a BET inhibitor, attenuates inflammation induced by viral RNA mimetic and reduces SARS-CoV-2 spike protein binding regardless of variants

Event: ESC Congress 2022

Topic: Pharmacotherapy

Session: Pericardial disease, myocardial disease, COVID-19

Access
Like
Thumbnail

Apabetalone (RVX-208) inhibits key drivers of vascular inflammation, calcification, and plaque vulnerability through a BET-dependent epigenetic mechanism

Event: ESC Congress 2019

Topic: Inflammation and Immunity

Session: Coronary artery disease inflammation

Access
Like
Thumbnail

Apabetalone (RVX-208) Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and in Inflamed Mouse Aorta

Event: ESC Congress 2018

Topic: Genetics, Epigenetics, ncRNA

Session: Late Breaking Basic and Translational Science - Vascular Biology

Access
Like
Thumbnail

Apabetalone (RVX-208) impacts key biomarkers and pathways associated with cardiovascular disease in patients with severe renal impairment

Event: ESC Congress 2017

Topic: CAD and comorbidities

Session: CAD and comorbidities

Access
Like
Thumbnail

Modulation of the complement cascade in cardiovascular disease patients by a bromodomain and extraterminal (BET) protein inhibitor

Event: ESC Congress 2016

Topic: Inflammation and microcirculation

Session: Inflammation and immunity

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources